Other formats:
BibTeX
LaTeX
RIS
@article{1779219,
author = {Hanes, Jozef and Kovac, Andrej and Kvartsberg, Hlin and Kontsekova, Eva and Fialova, Lubica and Katina, Stanislav and Kovacech, Branislav and Stevens, Eva and Hort, Jakub and Vyhnalek, Martin and Boonkamp, Lynn and Novak, Michal and Zetterberg, Henrik and Hansson, Oskar and Scheltens, Philip and Blennow, Kaj and Teunissen, Charlotte E. and Zilka, Norbert},
article_location = {Philadelphia},
article_number = {22},
doi = {http://dx.doi.org/10.1212/WNL.0000000000010814},
language = {eng},
issn = {0028-3878},
journal = {Neurology},
title = {Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias},
url = {https://doi.org/10.1212/WNL.0000000000010814},
volume = {95},
year = {2020}
}
TY - JOUR
ID - 1779219
AU - Hanes, Jozef - Kovac, Andrej - Kvartsberg, Hlin - Kontsekova, Eva - Fialova, Lubica - Katina, Stanislav - Kovacech, Branislav - Stevens, Eva - Hort, Jakub - Vyhnalek, Martin - Boonkamp, Lynn - Novak, Michal - Zetterberg, Henrik - Hansson, Oskar - Scheltens, Philip - Blennow, Kaj - Teunissen, Charlotte E. - Zilka, Norbert
PY - 2020
TI - Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
JF - Neurology
VL - 95
IS - 22
SP - "E3026"-"E3035"
EP - "E3026"-"E3035"
PB - Lippincott Williams & Wilkins
SN - 00283878
UR - https://doi.org/10.1212/WNL.0000000000010814
N2 - OBJECTIVE: To investigate whether tau phosphorylated at Thr217 (p-tau T217) assay in CSF can distinguish patients with Alzheimer disease (AD) from patients with other dementias and healthy controls. METHODS: We developed and validated a novel Simoa immunoassay to detect p-tau T217 in CSF. There was a total of 190 participants from 3 cohorts with AD (n = 77) and other neurodegenerative diseases (n = 69) as well as healthy participants (n = 44). RESULTS: The p-tau T217 assay (cutoff 242 pg/mL) identified patients with AD with accuracy of 90%, with 78% positive predictive value (PPV), 97% negative predictive value (NPV), 93% sensitivity, and 88% specificity, compared favorably with p-tau T181 ELISA (52 pg/mL), showing 78% accuracy, 58% PPV, 98% NPV, 71% specificity, and 97% sensitivity. The assay distinguished patients with AD from age-matched healthy controls (cutoff 163 pg/mL, 98% sensitivity, 93% specificity), similarly to p-tau T181 ELISA (cutoff 60 pg/mL, 96% sensitivity, 86% specificity). In patients with AD, we found a strong correlation between p-tau T217 and p-tau T181, total tau and β-amyloid 40, but not β-amyloid 42. CONCLUSIONS: This study demonstrates that p-tau T217 displayed better diagnostic accuracy than p-tau T181. The data suggest that the new p-tau T217 assay has potential as an AD diagnostic test in clinical evaluation. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that a CSF immunoassay for p-tau T217 distinguishes patients with AD from patients with other dementias and healthy controls.
ER -
HANES, Jozef, Andrej KOVAC, Hlin KVARTSBERG, Eva KONTSEKOVA, Lubica FIALOVA, Stanislav KATINA, Branislav KOVACECH, Eva STEVENS, Jakub HORT, Martin VYHNALEK, Lynn BOONKAMP, Michal NOVAK, Henrik ZETTERBERG, Oskar HANSSON, Philip SCHELTENS, Kaj BLENNOW, Charlotte E. TEUNISSEN and Norbert ZILKA. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. \textit{Neurology}. Philadelphia: Lippincott Williams \&{} Wilkins, 2020, vol.~95, No~22, p.~''E3026''-''E3035'', 10 pp. ISSN~0028-3878. Available from: https://dx.doi.org/10.1212/WNL.0000000000010814.
|
